Literature DB >> 11766369

[A male case of primary bilateral breast cancers during estrogen therapy for prostate cancer].

A Emoto1, N Nasu, H Mimata, Y Nomura, H Mizokuchi, M Wada.   

Abstract

An 82-year old man received total androgen blockade therapy (bilateral orchiectomy and 375 mg/day flutamide) for the treatment of stage C prostate cancer. Serum PSA levels were undetectable for 13 months and thereafter increased gradually. We administered estramustine phosphate sodium (EPS) instead of flutamide under the diagnosis of hormone refractory prostate cancer. EPS therapy was discontinued after 9 months because serum PSA levels increased again. Then, the patient complained of bilateral breast nodules and pain. Bilateral mammectomies were performed due to bilateral breast cancers which had been diagnosed by aspiration biopsies and radiographic examinations, but he died four months after the operations. Final pathological diagnosis was ductal adenocarcinoma of the breasts. Immunohistochemical study revealed expressions of PSA in the breast cancers. We diagnosed double cancers of the prostate and the breast because of the different expression patterns of progesterone receptor between them. We review the literatures and discuss the differential diagnosis of prostate cancer and PSA-producing breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11766369     DOI: 10.5980/jpnjurol1989.92.698

Source DB:  PubMed          Journal:  Nihon Hinyokika Gakkai Zasshi        ISSN: 0021-5287


  2 in total

1.  Synchronous bilateral breast cancer in a male patient following hormone therapy for prostate cancer.

Authors:  Yuko Kijima; Heiji Yoshinaka; Munetsugu Hirata; Yoshihisa Umekita; Sumika Matsukita; Takashi Arima; Masayuki Nakagawa; Hizuru Kumemura; Nobuo Hamada; Koichi Kaneko; Yawara Funasako; Shoji Natsugoe
Journal:  Int J Clin Oncol       Date:  2009-07-11       Impact factor: 3.402

2.  Development of male breast cancer in a patient with prostate cancer during androgen deprivation therapy.

Authors:  Hiroya Mizusawa; Akira Komatsu; Yuji Mimura; Toshitaka Maejima
Journal:  IJU Case Rep       Date:  2022-01-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.